Conditions: Metastatic Prostate Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 36
Healthy volunteers: no

Brief summary:
The purpose of this research study is to find out what effects (good and bad) Sutent has on you and your prostate cancer.

Detailed description:
The following rationale can be made for a Phase II trial to evaluate sunitinib malate (Sutent) for the therapy of progressive metastatic androgen-independent prostate cancer (AIPC) following prior docetaxel chemotherapy. Since most patients with metastatic AIPC following prior chemotherapy clinically progress rapidly, we believe that achieving a 30% freedom from clinical progression (PFS) (not including PSA progression) at 12 weeks represents biologically active therapy. Sunitinib malate (Sutent) represents a tolerable and convenient form of therapy with the potential for improving outcomes in AIPC.

Arms:
arm 1: Sunitinib Malate (Sutent) (50 mg/day on Days 1-28 of 42-day cycles)

Interventions: intervention 1: Sunitinib
Intervention descriptions: intervention 1: 50 mg/day orally each of Days 1-28 of each 6 week cycle

Protocol document: